Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
It was an obvious sell you spoofer. Don't you think it's a bit ghoulish to be spoofing about holding shares in a company doing badly, it's like pretending to know someone who has just died to get attention. Weirdo clown.
It's a sell, look at the price, it even dropped the SP because it was a 25k sell. If it was a buy, the price would have been higher and would have nudged up the SP (judging by the sell effect).
So.......we know it's a sell, big question now is where did Valju's 25k buy go to?
I've looked and looked but no sign of it.
Where could it have gone.
Spoofer and a clown
PIs' decision up to a point, you don't have to sell after an offer is accepted but your holding may go down in value later. Hard to know at what price/s the bulk of the shares are held at to workout a T/O price point, but 65p is a good starting point for a potential bidder to start at.
If you were successful you wouldn't spend your life here making dumb illiterate posts would you. Or lying about your life (Austin was funny tho).
Naw I've described you accurately which is why you always spend time getting my posts deleted
I enjoy it
Digby I normally ignore stuff like this but.......... he's a senior head in a French investment company with a good footprint in Novacyts sector. He is also an old school LinkedIn user, nice tight activity history, all business except for a couple of skiing and virtue signaling posts. He also promotes the companies in their portfolio.
I want it to be good news, however as NCYT have a 100mm cash in hand they prob aren't looking for an investment, so, either NCYT is going to invest in other companies via LeJans or NCYT is sniffing around their portfolio for some M&A opportunities.
It's a trade show, just a trade show. A trade show for lab equipment, just lab equipment. It looks perfectly ok to me. At the moment NCYT do most things badly. But, granted I'm just looking at a photo, there is nothing wrong with the stand, and importantly it seems to be in a premium location.
Meanwhile I wonder if DA noticed Musk didn't announce a 100 day review when he took over Twitter, straight in and change the business in the first week. That's a $54BB business with no money and 8k pax. NCYT is a $20mm business with $100mm ++ in the bank and 200 pax. Sort it out David.
How do you know it's not 11pm in an airport bar waiting on a flight after doing an 80 hour week travelling and meeting clients. I don't think you lot have a clue about the hours people in those roles put in. He probably works across an 8hr time diff on his territory, so a 2am or 6am conf. call would not be unusual.
Not a great sign, 1 yr in and DA has hired several business heads. Were they hired because no-one internally could grasp his vision for the business or does he not have a plan so has hired other people to do the job. Problem is, new hires don't arrive with a vision, they have the experience to implement and drive a strategy forward, if there is one, or over time they can make their own vision and implement it. But tick tock these hires are a year late and I'm not seeing the groundwork, I have concerns the BoD will hide behind these new business heads and them take responsibility for any failure.
Thanks Simmulla.
CercleFinance.com) - The Biosynex stock fell on the Paris Stock Exchange this Friday, as the laboratory specializing in
molecular biology tests unveiled unsurprising half-year results last night.
The Alsatian group reported a turnover of 142.2 million euros over the first six months of the year, down 37% compared
to the first half of the previous year.
As expected, the company observed, in the second quarter, a sharp decrease in sales of products related to Covid-19, to 17.3 million euros against 140.4 million euros a year earlier, against a backdrop of improvement of the health situation.
The share of Covid-19 products - which represented 89% of sales in the first quarter of 2022 - thus fell to 54% in the second quarter of 2022.
Gross operating surplus (EBITDA) stood at 50.3 million euros. euros, against 100.4 million a year earlier, ie a margin of 35.3%, for a consolidated net profit of 30.6 million euros, against 70.5 million euros a year earlier.
Biosynex also announced on Friday the signing of a licensing and marketing agreement with ProciseDx under which the production of tests for monitoring patients with chronic bowel disease (IBD) from the American company will be transferred to France. .
Biosynex specifies that it increased its stake in ProciseDx from 31.2% to 42.7% at
At 3:45 p.m., the Biosynex share listed on the Paris Stock Exchange yielded 1%.
Why not use the money to pivot a bit and launch Novacyt Pharma Investments to invest and buy bonds in tech start-ups, added benefits is partnership and m&a opportunities with main business. Access to these companies would keep NCYT at the forefront with easy excess to new tech as a 'Global First Responder' (if that's still the strapline).
But no buybacks pls, I hate them, like paying a $1.20 for $1 bill, but can't believe they didn't issue new shares near the top of the SP in the middle of covid, they could have raised £100's of millions, £500million easy for investment.
And what happens to the SP of a company that decides to earn a pathetic few % on cash in the bank rather than invest it in growing the business. Yes the SP drops because the market ignores the money. Because if you want to earn 5% interest on an investment you put your money in a investment fund NOT into a Pharma company. I mean why trust a Pharma company to do financial investments, should they not be doing pharma type things with the money